Taking Research and Development to the Clinic: Issues for Physicians AAAS/FDLI Colloquium I Diagnostics and Diagnoses Paths to Personalized Medicine Howard.

Slides:



Advertisements
Similar presentations
Genetics and Genomics in Clinical Medicine
Advertisements

1 Testing in the Open Market Testing in the Open Market AAAS Colloquium on Personalized Medicine: Planning for the Future June 2, 2009 Courtney C. Harper,
Personalized medicine: Looking beyond the science Pamela Sankar, PhD Department of Medical Ethics University of Pennsylvania AAAS-FDLI Personalized Medicine:
PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Regulation of Consumer Tests in California AAAS Meeting June 1-2, 2009 Beatrice OKeefe Acting Chief, Laboratory Field Services California Department of.
Health IT and Personalized Medicine Policy Implications John Glaser, PhD Senior Advisor, ONC/HHS Vice President and CIO Partners HealthCare October 26,
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning” A Report of the American College of Cardiology Foundation Task Force on Clinical.
Genomic Medicine Pilot Demonstration Projects
Ellen Wright Clayton, MD, JD. Genome wide tests will become part of clinical care in the near future Access to this information will be difficult, if.
Regulatory Framework Leigh Shaw, Director.
4 pictures 1 word! Learning Outcomes Examine how future medicine may take into account an individuals genome for personalised medicine Distinguish between.
Improving Office Care for Chest Pain Thomas D. Sequist, MD MPH Associate Professor of Medicine and Health Care Policy Brigham and Women ’ s Hospital, Division.
Genomic Medicine: A Revolution in Medical Practice in the 21 st Century Francis S. Collins, M.D., Ph.D. National Human Genome Research Institute World.
Unique Challenges in MPNs 2012 Bay Area MPN Patient Symposium Laura C. Michaelis, MD Loyola University Medical Center.
Genetic Analysis in Human Disease
Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.
Approaches to incorporating pharmacoeconomic data into early drug discovery Kevin Sheehy Acting CEO Medicines New Zealand.
Mark W Linder, Ph.D., DABCC, FACB Medical Director, EVP Operations Kristen K. Reynolds Ph.D. Associate Medical Director, VP Laboratory Operations Mark.
©2007 RALPH SNYDERMAN Third Annual Prospective Health Care Conference "Where are We Now?" Ralph Snyderman, MD Chancellor Emeritus, Duke University November.
Dr. Almut Nebel Dept. of Human Genetics University of the Witwatersrand Johannesburg South Africa Significance of SNPs for human disease.
1 SIMG Florence ppt The Horizons of Predictive Medicine Dr Ian Gilham Worldwide Director, Predictive Medicine Glaxo Wellcome Research and Development.
1 PGRx: An Interactive Software System for Integrating Clinical Genotyping with Prescription Drug Safety Assurance. Michael D. Kane, Ph.D. Assistant Professor.
Genetic Testing in Genomic Medicine Gail H. Vance M.D. Professor, Department of Medical & Molecular Genetics Indiana University School of Medicine.
By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Introduction to Molecular Epidemiology Jan Dorman, PhD University of Pittsburgh School of Nursing
Direct-to-Consumer Genetic Testing Developed by Dr. June Carroll, Ms. Shawna Morrison and Dr. Judith Allanson Last updated April 2014.
Pharmacogenomics and personalized medicines Jean-Marie Boeynaems
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
Opportunities for Big Data in Medical Records Mike Conlon, PhD
Evidence-Based Medicine: Promises and Problems Victor R. Fuchs Henry J. Kaiser Jr. Professor Emeritus Stanford University Nuffield Trust, London, 12 May.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Sales Trainer for PGXL Laboratories
Chapter 13 Carrier Screening. Introduction Carrier screening involves testing of individuals for heterozygosity for genes that would produce significant.
Should individuals be able to directly access their genetic information without physician involvement? Jeff Gulcher MD PhD Chief Scientific Officer and.
Study Designs Afshin Ostovar Bushehr University of Medical Sciences Bushehr, /4/20151.
Adult-Onset Disease The Example of Colon Cancer Summer, 2012.
Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.
Introduction: Medical Psychology and Border Areas
APPLIED PSYCHOLOGY LABORATORY East Tennessee State University Johnson City, Tennessee INTRODUCTION CONTACT:
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
Looking at Frailty Through a New Lens John Strandmark, M.D. ©AAHCM.
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health (BMG) The use of.
Pompe Disease Evidence Evaluation Michael Watson, PhD, on behalf of Piero Rinaldo, MD, PhD, and the Decision-Making Workgroup October 1, 2008.
Dr Godfrey Grech University of Malta
Organization of statistical research. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and.
The Diagnostic Process A BRIEF OVERVIEW diagnostic process What is it? to figure out to problem solve method scheme.
Copyleft Clinical Trial Results. You Must Redistribute Slides The American College of Cardiology Foundation / American Heart Association Clopidogrel Recommendations.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
Pharmacogenetics.
BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
How Genetic Variants Impact the Safety and Effectiveness of Drugs Pharmacogenetics © PGXL Laboratories.
European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.
Jan 2002 EDMA The central role of the Medical Laboratory in a World of Managed Health An EDMA presentation of the benefits of in vitro testing as a basis.
Pharmacogenomics: Improving the Dynamic of Care in Medication Management 1.
© 2010 Jones and Bartlett Publishers, LLC. Chapter 12 Clinical Epidemiology.
Estimating Absolute Risk Reductions Associated with Interventions in Patients with Type 2 Diabetes Jim Mold, M.D., M.P.H. Brian Firestone, MS2.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
Living on the Edge (of Translational Informatics) Opportunities and Challenges for Integrating Bioinformatics into the Clinical Realm Russ B. Altman (Stanford.
What should a psychiatrist know about genetics?
Moiz Bakhiet, MD, PhD, Professor and Chairman
New research areas in personalised medicines
Pharmacogenomics Rita Leone, RN, MSN, CMSRN.
Mahla sattarzadeh Kerman University of Medical Sciences
Knowledge l Action l Impact
Regulatory perspective
Pharmacogenomics Genes and Drugs.
Introduction to Pharmacogenetics
Using clinical trial data as real-world evidence
Presentation transcript:

Taking Research and Development to the Clinic: Issues for Physicians AAAS/FDLI Colloquium I Diagnostics and Diagnoses Paths to Personalized Medicine Howard Levy, MD, PhD Johns Hopkins University June 1, 2009

What is Personalized Medicine? Biomarkers and genetic tests Customization of medical care to the individual patient All aspects of carenot just biomarkers, not just genetics

Challenges & Opportunities Self-evident truths: Physicians want to help patients Time & resources are scarce Can biomarkers improve both?

Using a Biomarker Select a test Order a test Get it paid for Get it done Receive result Understand result Archive result Access result (now & future) Apply result in clinical care

Clinical Utility Does the biomarker improve clinical care? Pharmacogenetics Predictive testing Faster or more precise diagnostics

Clinical Utility What are the costs? Financial Time/Resources Social/Ethical/Legal Medical (incorrect conclusions) Psychological

Pharmacogenetics The right drug At the right time In the right dose Efficacy Adverse events

Warfarin Dosing Fixed-dose Clinical algorithm (weight, age, sex) This is personalized medicine! Pharmacogenetic (VKORC1 & CYP2C9) PGx explains ~40% of dose variability Clinical + PGx explains ~54% of variability

Intl Warfarin PGx Consortium N Engl J Med 360(8): February 19, 2009

Warfarin PGx Clinical Utility Likely to achieve therapeutic dose faster Relatively easy to order & receive results Often covered by 3 rd parties Algorithm freely available Improved efficacy & fewer adverse events? Seems likely Still being studied

Warfarin PGx Clinical Utility Limitations: Needs to be done promptly at initiation of therapy ~45% of dose variability unexplained Environmental factors remain important

Drug Metabolism: CYP450 >50% of all drugs Prodrug Active Drug Active Inactive Relevant Factors: Other drugs Diet & environment Genetic variants

CYP450 PGx Clinical Utility Genetic testing is available Is PGx testing better than trial & error? Drug choice & dosing recommendations? What if there are no alternatives? Psychological distress Relative risk Genetic determinism

Genetic Determinism Belief that clinical outcomes are inexorably defined by genetic factors Ignores: Genetic/epigenetic modifiers Environmental modifiers Variable expression Reduced penetrance

Predictive Testing Its tough to make predictions, especially about the future -Dan Quayle, Casey Stengel, et al. The future aint what it used to be -Yogi Berra

Genetic Risk Assessment Family History Varies over time DNA variants Stable over time Relative risk

GWAS: Genome-Wide Association Studies Really BIG case-control study 1000s of subjects 500,000 to 1,000,000 SNPs Power to detect small effect sizes Subject to same errors & biases as any other epidemiologic study

CAD Risk Assessment: Gene Environment Smoking, HTN, DM, etc: OR SNPs: OR (usually ) Family History: intermediate

Heritability Proportion of disease predisposition that is due to inherited factors SNPssmall amount Other heritable factors (DNA & Non-DNA variants) Current tests assess only a small portion of heritability

Analytical & Clinical Validity Is the test accurate? Does the biomarker correlate clinically (retrospective vs. prospective study)? How are results of multiple tests combined? Validity is often assumed when test is offered clinically.

The Fallacy of Genetic Determinism Positive tests Disease Negative tests Health

Clinical Utility of Genetic Testing for Common Disease? What do the results mean? Small effect size Environmental factors Fallacy of genetic determinism Undue anxiety/false reassurance?

Clinical Utility of Genetic Testing for Common Disease? Modify therapy to reduce risk? Motivation to change behavior? Smoking, exercise & diet campaigns Does the Personalized Medicine model work?

Clinical Utility of Genetic Testing for Common Disease? Cost Large amounts of clinical data Paucity of tools to integrate data Uncertain plan of action May be appropriate for some patients

PM Opportunities Improved diagnostics Improved therapeutics Improved health maintenance More efficient use of time Lower health care costs Patient & physician satisfaction

PM Challenges Clinician Education Test indications Test validity Result interpretation Clinical utility Integration into clinical care

Clinician Education Learning Preferences Clinically relevant Just in time (point of care) Fast (<2 minutes) Increasingly Internet-based 2 o sources ( authority vs. accuracy) GeneFacts

PM Challenges Test Validity Transparency Providers lack time & knowledge to evaluate Regulation Slows progress, limits access, cost Paternalism vs. Autonomy

PM Challenges Test Ordering & Payment Facilitating ordering the correct test DTC testing vs. physician gatekeeper 3 rd party payers Paternalism vs. Autonomy

PM Challenges Receiving, Archiving and Accessing Results EHRs Can also prompt provider to order/use tests PHRs Information sharing between providers Does the data already exist? Privacy & Security

PM Challenges Clinical Utility Better assessment of health factors Genetic Environmental Better tools to combine environment, family history & biomarkers Studies of actual clinical outcomes (Hype Hope Reality)

The Art of Medicine Evidence-based medicine Based on population studies Individual people Autonomous Variably reliable Ever-changing environment Personalized Medicine Requires knowing & monitoring the patient and therapy at the individual level